Mark Acosta

750 total citations
16 papers, 314 citations indexed

About

Mark Acosta is a scholar working on Pathology and Forensic Medicine, Immunology and Dermatology. According to data from OpenAlex, Mark Acosta has authored 16 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 7 papers in Immunology and 6 papers in Dermatology. Recurrent topics in Mark Acosta's work include Lymphoma Diagnosis and Treatment (8 papers), T-cell and Retrovirus Studies (7 papers) and Cutaneous lymphoproliferative disorders research (6 papers). Mark Acosta is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), T-cell and Retrovirus Studies (7 papers) and Cutaneous lymphoproliferative disorders research (6 papers). Mark Acosta collaborates with scholars based in United States, Italy and France. Mark Acosta's co-authors include Chalid Assaf, Wolfram Sterry, Yijun Sun, Madeleine Duvic, Ann Martin, A. Negro‐Vilar, H. Miles Prince, David J. Straus, John T. Kanegaye and David Bank and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Mark Acosta

16 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Acosta United States 8 158 152 130 84 59 16 314
E. Poszepczynska-Guigné France 8 197 1.2× 196 1.3× 85 0.7× 41 0.5× 87 1.5× 11 368
Gökhan Okan Türkiye 10 74 0.5× 74 0.5× 45 0.3× 32 0.4× 61 1.0× 22 287
Patrick Jégo France 8 148 0.9× 48 0.3× 95 0.7× 21 0.3× 73 1.2× 10 319
Yi Chun Lai United States 12 66 0.4× 126 0.8× 56 0.4× 42 0.5× 37 0.6× 28 329
Merete Engelhart Denmark 6 71 0.4× 79 0.5× 53 0.4× 13 0.2× 21 0.4× 7 251
B. Mascagni Italy 8 249 1.6× 99 0.7× 114 0.9× 9 0.1× 33 0.6× 10 316
M. F. Avril France 6 192 1.2× 182 1.2× 43 0.3× 58 0.7× 109 1.8× 9 329
Dušanka Martinović Kaliterna Croatia 12 136 0.9× 61 0.4× 77 0.6× 10 0.1× 54 0.9× 44 309
Femke Bonte‐Mineur Netherlands 10 112 0.7× 39 0.3× 53 0.4× 11 0.1× 40 0.7× 12 235
Elisabetta Vantaggiato Italy 8 66 0.4× 22 0.1× 61 0.5× 62 0.7× 26 0.4× 14 290

Countries citing papers authored by Mark Acosta

Since Specialization
Citations

This map shows the geographic impact of Mark Acosta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Acosta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Acosta more than expected).

Fields of papers citing papers by Mark Acosta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Acosta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Acosta. The network helps show where Mark Acosta may publish in the future.

Co-authorship network of co-authors of Mark Acosta

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Acosta. A scholar is included among the top collaborators of Mark Acosta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Acosta. Mark Acosta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Iyer, Swaminathan P., Shaker R. Dakhil, Michi M. Shinohara, et al.. (2024). Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial. PubMed. 2(1). 100055–100055. 1 indexed citations
2.
Lansigan, Frederick, Sarah McCue Horwitz, Lauren Pinter‐Brown, et al.. (2020). Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clinical Lymphoma Myeloma & Leukemia. 20(11). 744–748. 9 indexed citations
3.
4.
Sawas, Ahmed, Helen Ma, Andrei R. Shustov, et al.. (2019). Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL). Blood. 134(Supplement_1). 4050–4050. 5 indexed citations
5.
6.
Stuver, Robert, Niloufer Khan, Marc Schwartz, et al.. (2018). Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry. Blood. 132(Supplement 1). 2926–2926. 2 indexed citations
7.
Lansigan, Frederick, Sarah McCue Horwitz, Lauren Pinter‐Brown, et al.. (2016). Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study. Blood. 128(22). 4150–4150. 5 indexed citations
8.
Gordon, Christopher J., et al.. (2016). Toward automated face detection in thermal and polarimetric thermal imagery. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 9842. 984212–984212. 1 indexed citations
9.
Prince, H. Miles, Madeleine Duvic, Ann Martin, et al.. (2010). Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology. 28(11). 1870–1877. 152 indexed citations
10.
Foss, Francine M., Nelida Sjak-Shie, André Goy, et al.. (2007). Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.. Blood. 110(11). 3449–3449. 13 indexed citations
11.
Foss, Francine M., Madeleine Duvic, Larisa J. Geskin, et al.. (2006). Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.. Blood. 108(11). 2712–2712. 4 indexed citations
12.
Foss, Francine M., Nelida Sjak-Shie, André Goy, et al.. (2006). A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis.. Blood. 108(11). 2461–2461. 6 indexed citations
13.
Kanegaye, John T., et al.. (2003). High-Dose Rectal Midazolam for Pediatric Procedures: A Randomized Trial of Sedative Efficacy and Agitation. Pediatric Emergency Care. 19(5). 329–336. 27 indexed citations
14.
Marchena‐Gómez, Joaquín, et al.. (2003). Use of the preoperative levels of CEA in patients with colorectal cancer.. PubMed. 50(52). 1017–20. 16 indexed citations
15.
Mainwaring, Richard D., et al.. (2000). Pharmacokinetic Evaluation of Triiodothyronine Supplementation in Children After Modified Fontan Procedure. Circulation. 101(12). 1423–1429. 31 indexed citations
16.
Bradley, John S., et al.. (1992). Pharmacokinetics and safety of intramuscular injection of concentrated certriaxone in children.. PubMed. 11(11). 961–4. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Poszepczynska-Guigné Breakdown of academic impact, for papers by Gökhan Okan Breakdown of academic impact, for papers by Patrick Jégo Breakdown of academic impact, for papers by Yi Chun Lai Breakdown of academic impact, for papers by Merete Engelhart Breakdown of academic impact, for papers by B. Mascagni Breakdown of academic impact, for papers by M. F. Avril Breakdown of academic impact, for papers by Dušanka Martinović Kaliterna Breakdown of academic impact, for papers by Femke Bonte‐Mineur Breakdown of academic impact, for papers by Elisabetta Vantaggiato
Rankless by CCL
2026